Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Delphine Lebon

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
Blood Advances|September 9, 2025
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignanciesMichael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22<sup>+</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
Blood Advances|September 9, 2025
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignanciesMichael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22<sup>+</sup> Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic LeukemiaPatrice Chevallier, Thibaut Leguay, Marc Delord, et al.
Leukemia|May 12, 2026
Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangementBenoit Ducourneau, Arnaud Pages, Stéphanie Struski, et al.
Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.
Leukemia|January 23, 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trialFrancois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, et al.
Pageof 5